NO307498B1 - FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn - Google Patents

FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn Download PDF

Info

Publication number
NO307498B1
NO307498B1 NO920915A NO920915A NO307498B1 NO 307498 B1 NO307498 B1 NO 307498B1 NO 920915 A NO920915 A NO 920915A NO 920915 A NO920915 A NO 920915A NO 307498 B1 NO307498 B1 NO 307498B1
Authority
NO
Norway
Prior art keywords
impotence
erection
preparation
vip
injection
Prior art date
Application number
NO920915A
Other languages
English (en)
Norwegian (no)
Other versions
NO920915D0 (no
NO920915L (no
Inventor
Thomas Gerstenberg
Jan Fahrenkrug
Bent Ottesen
Original Assignee
Senetek Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senetek Plc filed Critical Senetek Plc
Publication of NO920915D0 publication Critical patent/NO920915D0/no
Publication of NO920915L publication Critical patent/NO920915L/no
Publication of NO307498B1 publication Critical patent/NO307498B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Load-Engaging Elements For Cranes (AREA)
  • Cosmetics (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Detergent Compositions (AREA)
  • Revetment (AREA)
  • Meat, Egg Or Seafood Products (AREA)
NO920915A 1989-09-18 1992-03-09 FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn NO307498B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/408,754 US5236904A (en) 1989-09-18 1989-09-18 Erection-inducing methods and compositions
PCT/US1990/005237 WO1991004039A1 (en) 1989-09-18 1990-09-14 Erection-inducing methods and compositions

Publications (3)

Publication Number Publication Date
NO920915D0 NO920915D0 (no) 1992-03-09
NO920915L NO920915L (no) 1992-03-09
NO307498B1 true NO307498B1 (no) 2000-04-17

Family

ID=23617626

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920915A NO307498B1 (no) 1989-09-18 1992-03-09 FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn

Country Status (23)

Country Link
US (1) US5236904A (cs)
EP (1) EP0493485B1 (cs)
JP (1) JP3149946B2 (cs)
KR (1) KR100230720B1 (cs)
AT (1) ATE210994T1 (cs)
AU (1) AU641184B2 (cs)
BR (1) BR9007662A (cs)
CA (1) CA2065270C (cs)
CZ (1) CZ280446B6 (cs)
DE (1) DE69033881T2 (cs)
DK (1) DK0493485T3 (cs)
ES (1) ES2170050T3 (cs)
FI (1) FI104231B (cs)
GE (1) GEP19981264B (cs)
HU (1) HU208088B (cs)
IL (1) IL95505A (cs)
LT (1) LT3544B (cs)
LV (1) LV10198B (cs)
NO (1) NO307498B1 (cs)
RO (1) RO116346B1 (cs)
RU (1) RU2098120C1 (cs)
SK (1) SK452490A3 (cs)
WO (1) WO1991004039A1 (cs)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A (en) * 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
PT1280531E (pt) * 2000-05-12 2007-02-28 Novalar Pharmaceuticals Inc Formulação consistindo de mesilato de fentolamina e sua utilização
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 (en) * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
CA2601279A1 (en) * 2005-03-07 2006-09-14 Mondobiotech Licensing Out Ag Formulation for aviptadil
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
CA2804755C (en) * 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US9913748B2 (en) 2009-10-30 2018-03-13 Avner Spector Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
GB201221046D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
WO2019102310A1 (en) 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 (de) * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra

Also Published As

Publication number Publication date
GEP19981264B (en) 1998-07-07
US5236904A (en) 1993-08-17
SK279489B6 (sk) 1998-12-02
EP0493485A1 (en) 1992-07-08
NO920915D0 (no) 1992-03-09
IL95505A (en) 1997-03-18
FI104231B1 (fi) 1999-12-15
SK452490A3 (en) 1998-12-02
RO116346B1 (ro) 2001-01-30
ES2170050T3 (es) 2002-08-01
KR100230720B1 (en) 1999-11-15
JPH05500513A (ja) 1993-02-04
HU9200874D0 (en) 1992-05-28
LT3544B (en) 1995-11-27
HUT60633A (en) 1992-10-28
JP3149946B2 (ja) 2001-03-26
CA2065270C (en) 2003-01-14
NO920915L (no) 1992-03-09
AU641184B2 (en) 1993-09-16
DE69033881T2 (de) 2002-09-12
CZ280446B6 (cs) 1996-01-17
FI921136A7 (fi) 1992-03-17
LV10198B (en) 1995-08-20
CA2065270A1 (en) 1991-03-19
RU2098120C1 (ru) 1997-12-10
AU6440490A (en) 1991-04-18
FI921136A0 (fi) 1992-03-17
HK1011292A1 (en) 1999-07-09
CZ452490A3 (en) 1995-09-13
ATE210994T1 (de) 2002-01-15
HU208088B (en) 1993-08-30
EP0493485B1 (en) 2001-12-19
EP0493485A4 (en) 1993-08-18
DK0493485T3 (da) 2002-03-18
BR9007662A (pt) 1992-07-21
LTIP1579A (en) 1995-06-26
LV10198A (lv) 1994-10-20
FI104231B (fi) 1999-12-15
WO1991004039A1 (en) 1991-04-04
DE69033881D1 (de) 2002-01-31

Similar Documents

Publication Publication Date Title
NO307498B1 (no) FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn
US5447912A (en) Erection-inducing methods and compositions
Rajfer et al. Prevalence of corporeal venous leakage in impotent men
Lue Impotence: a patient's goal-directed approach to treatment
Gerstenberg et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure
Buvat et al. Venous incompetence: critical study of the organic basis of high maintenance flow rates during artificial erection test
US6258373B1 (en) Treatment of sexual dysfunction in certain patient groups
Kiely et al. Assessment of the immediate and long‐term effects of pharmacologically induced penile erections in the treatment of psychogenic and organic impotence
US6110489A (en) Use of quinolines and quinolones to treat male erectile dysfunction
Knispel et al. Influence of cause on choice of therapy in 174 patients with erectile dysfunction
Wespes et al. Impotence due to corporeal veno-occlusive dysfunction: long-term follow-up of venous surgery
Vickers et al. The current cavernosometric criteria for corporovenous dysfunction are too strict
US6132753A (en) Treatment of sexual dysfunction in certain patient groups
US6303135B1 (en) Use of quinolines and quinolones to treat male erectile dysfunction
Fouda et al. Priapism: an avoidable complication of pharmacologically induced erection
Iacono et al. Evaluation of penile deep arteries in psychogenic impotence by means of duplex ultrasonography
WO2002019997A1 (en) Pde iii inhibitors for treating sexual dysfunction
HK1011292B (en) Erection-inducing methods and compositions
Mooradian et al. Biweekly intracavernous administration of papaverine for erectile dysfunction
US6426084B1 (en) Treatment of sexual dysfunction in certain patient groups
Parrott et al. Penile vein dissection: a study of its long-term efficacy in impotence
Jantos et al. Pharmacocavernosography in the evaluation of erectile failure
Mouritsen et al. The intracavernous injection of papaverine as a diagnostic procedure in patients with erectile dysfunction
Anglade et al. Male sexual dysfunction
Sargin et al. Correlation between intracavernous papaverine injection, Doppler analysis and cavernosography in impotent patients

Legal Events

Date Code Title Description
MK1K Patent expired